Recordati S.p.A. · MIL:REC

Recordati — Investor Presentation (May 2000)

35 slides from Recordati's investor presentation, May 10, 2000

  1. Slide 1: Acquisizioni in Europa per un traguardo a 1.000 miliardi

    Acquisizioni in Europa per un traguardo a 1.000 miliardi Milano, 10 Maggio 2000

  2. Slide 2: Relatori

    Acquisizioni in Europa per un traguardo a 1.000 miliardi Relatori: • Giovanni Recordati Chairman and Chief Executive Officer • Fritz Squindo Chief Financial Officer • Walter Bevilacqua Vice President and Director Corporate Developmen Developme 1

  3. Slide 3: Fritz Squindo, Chief Financial Officer

    Fritz Squindo Chief Financial Officer 2

  4. Slide 4: Where we come from: 1997-1999 Highlights

    Where we come from: 1997-1999 HIGHLIGHTS 3

  5. Slide 5: 1997-1999 Highlights

    1997-1999 HIGHLIGHTS CAGR (billion lira) 1997 1998 1999 1997-1999 Net Sales 372.3 416.1 526.3 18.9% Gross Profit 185.5 213.3 281.7 23.2% as % of sales 49.8% 51.3% 53.5% Operating Income Before R&D 66.6 74.2 95.9 20.0% as % of sales 17.9% 17.8% 18.2% Operating Income 31.9 34.1 37.2 as % of sales 8.6%

  6. Slide 6: Where we are: Results Q1 2000

    Where we are: RESULTS Q1 2000 P&L TRENDS SALES & MARGINS BY BUSINESS AREA CAPITAL EMPLOYED 6

  7. Slide 7: Results Q1 2000

    RESULTS Q1 2000 Q1 (billion lira) 1999 2000 Delta Net Sales 127.3 147.8 16.1% Gross Profit 66.7 86.1 29.1% as % of sales 52.4% 58.3% Operating Income Before R&D 20.0 34.9 74.1% as % of sales 15.7% 23.6% R&D Expenses 13.1 17.6 33.8% as % of sales 10.4% 11.9% Operating Income 6.9 17.3 150.9 as % of sa

  8. Slide 8: P&L Trends

    P&L TRENDS (as % of Net Sales) 1999 1999 2000 Q1 Q2-Q4 Q1 Gross Profit 52.4 53.9 58.3 SG&A (a) 36.7 34.8 34.6 Operating Income before R&D 15.7 19.0 23.6 R&D 10.3 11.4 11.9 Operating Income 5.4 7.6 11.7 (a) Includes amortization of goodwill 8

  9. Slide 9: Results Q1 2000

    RESULTS Q1 2000 Q1 (billion lira) 1999 2000 Delta Net Sales 127.3 147.8 16.1% Gross Profit 66.7 86.1 29.1% as % of sales 52.4% 58.3% Operating Income Before R&D 20.0 34.9 74.1% as % of sales 15.7% 23.6% R&D Expenses 13.1 17.6 33.8% as % of sales 10.4% 11.9% Operating Income 6.9 17.3 150.9 as % of sa

  10. Slide 10: Where we are: Results Q1 2000

    Where we are: RESULTS Q1 2000 P&L TRENDS SALES & MARGINS BY BUSINESS AREA CAPITAL EMPLOYED 10

  11. Slide 11: Sales & Margins by Business Area

    SALES & MARGINS BY BUSINESS AREA PHARMACEUTICALS PHARMA CHEMICALS (billion lira) Q1-99 Q1-00 Delta Q1-99 Q1-00 Delta Net Sales 90.7 108.8 + 20.0% 36.6 39.0 + 6.6% 4.1 11.7 2.8 5.6 Operating Margin 4.5% 10.8% + 185.4% 7.7% 13.5% + 100.0% 11

  12. Slide 12: Capital Employed

    CAPITAL EMPLOYED 1999 2000 (billion lira) 31/12 31/03 Net Working Capital for Operations 103.3 126.6 Net Non-current Assets 233.5 216.7 Reserves for Long - term Liabilities (36.5) (35.5) CAPITAL EMPLOYED 300.3 307.8 Net Debt 86.9 77.7 Shareholders’ Equity 213.4 230.1 FINANCING OF 300.3 307.8 CAPITAL

  13. Slide 13: Where we are going: 2000-2003 Targets

    Where we are going: 2000-2003 TARGETS NET SALES & OPERATING MARGIN CAPITAL EMPLOYED 13

  14. Slide 14: 2000-2003 Targets

    2000-2003 TARGETS CAGR (billion lira) 1999 2000 2003 1999-2003 Net Sales 526.3 593.5 1000 17.4% Gross Profit 281.7 329.9 561 as % of sales 18.8% 53.5% 55.6% 56.1% R&D 58.7 65.3 100 14.2% as % of sales 11.2% 11.0% 10.0% Operating Income 37.2 61.6 130 as % of sales 36.7% 7.1% 10.4% 13.0% EPS (lira) 93

  15. Slide 15: Evolution of Net Sales & Operating Margin

    EVOLUTION OF NET SALES & OPERATING MARGIN (billion lira) 1000 1000 905 16,0% 825 900 14,0% 800 594 13.0% 12,0% 700 526 12.1% 600 11.0% 10,0% 10.4% 500 8,0% 400 7.1% 6,0% 300 4,0% 200 100 2,0% 0 0,0% 1999 2000 2001 2002 2003 Net Sales Operating Margin 15

  16. Slide 16: Evolution of Capital Employed

    EVOLUTION OF CAPITAL EMPLOYED (billion lira) 1999 2000 2001 2002 2003 Net Working Capital for Operations 103 136 151 169 182 Net Non-current Assets 233 424 408 397 386 Reserves for Long - term Liabilities (36) (39) (36) (33) (30) CAPITAL EMPLOYED 300 521 523 533 538 Net Debt 87 277 246 208 157 Share

  17. Slide 17: Walter Bevilacqua

    Walter Bevilacqua Vice President and Director Corporate Development 14

  18. Slide 18: How we are going to get there: Drivers of Growth

    How we are going to getTHE STARTING POINT there:DRIVERS OF GROWTH RECORDATI IN 2003 BEYOND 2003 18

  19. Slide 19: The Starting Point

    THE STARTING POINT •A new level of sales & profitability CAGR Growth 1997-1999 1999-2000 Net Sales +18.9% +16.1% Gross Profit +23.2% +29.1% •Concentration on core activities and key products 19

  20. Slide 20: Drivers of Growth

    DRIVERS OF GROWTH  Stronger, more efficient market presence  Zanidip®  Acquisitions  Licensed-in products  R&D Pipeline 20

  21. Slide 21: Drivers of Growth

    DRIVERS OF GROWTH  Stronger, more efficient market presence  Zanidip®  Acquisitions  Licensed-in products  R&D Pipeline 21

  22. Slide 22: Efficient Market Presence

    EFFICIENT MARKET PRESENCE • Italy, Spain: work done in 1998-1999 (Italy, Market Audits) Jan-Feb Jan-Feb Trend 1999 2000 Growth over prior year; value 6.2% 13.6% Market 9.9% 23.8% Recordati Market share; value Relative (to Roche) 23.3% 25.3% 108 Absolute 1.31% 1.43% 109 • France, Portugal: 2000-2001

  23. Slide 23: Strong Market Presence

    STRONG MARKET PRESENCE  What is market share good for: - efficient local operations - share of voice for new product introduction - attractive in-licensing partner  Where is Recordati? - strong in Italy - France covered with acquisition - build-up planned in Portugal, Spain 23

  24. Slide 24: Drivers of Growth

    DRIVERS OF GROWTH  Stronger, more efficient market presence  Zanidip®  Acquisitions  Licensed-in products  R&D Pipeline 24

  25. Slide 25: Zanidip Italy

    ZANIDIP® ITALY • Excellent performance where it has been introduced Jan-Feb Jan-Feb Italy (billion lira) Growth % 1999 2000 Zanidip® 3.7 7.1 91 Recordati licensees 2.4 3.2 34 Norvasc® 34.4 40.0 16 Rest of class 86.0 88.8 3 Relative market share of Trend Zanidip® to: 11.0 18.0 164 Norvasc® 4.3 8.0 18

  26. Slide 26: Zanidip International Expansion

    ZANIDIP® INTERNATIONAL EXPANSION •World pharmaceutical markets, 1999 $ bn % of (billion lira) world US 86. 41 Japan 0 23 France, 47. 14 Germany 6 12 Source: Scrip Italy, Uk, Spain 29. 9 1999 2000 2003 •Zanidip® launched in: 24. Q1 Q1 Q4 1 US, Japan - - - France, Germany - -  Italy, Uk, Spain   

  27. Slide 27: Drivers of Growth

    DRIVERS OF GROWTH  Stronger, more efficient market presence  Zanidip®  Acquisitions  Licensed-in products  R&D Pipeline 27

  28. Slide 28: Bouchara

    BOUCHARA (FF million) 1999(a) Net Sales Pharmaceuticals - France 350 - Export 110 460 Manufacturing 13 0 Total Sales 590 Operating Margin 10% Purchase Price (preliminary) 750 Net debt - Net worth 250 All data preliminary and subject to audit; transaction subject to contract (a) Bouchara fiscal year

  29. Slide 29: Bouchara

    BOUCHARA Pharmaceuticals France, 1999 (a) Therapeutic area Units (millions) Rank Revenues Rank in class (FF millions) in class Cough & Cold 214 of which - Exomuc 5.3 3 95 3 - Neo- codion 8.8 1 65 2 - Isofra 3.8 2 29 2 Antibiotics & Anti-infectives 8 of which - Amodex 5.3 3 2 59 5 - Panfurex 1.5 2 21

  30. Slide 30: Acquisitions & Licensed-in Products

    ACQUISITIONS & LICENSED-IN PRODUCTS  In the target numbers: - Bouchara - New licenses, 30 billion lira  Not in the target numbers: - Acquisitions in Portugal, Spain - Additional licenses 30

  31. Slide 31: Upside, other

    UPSIDE, other  Not in the target numbers: - Zanidip® in US, Japan 31

  32. Slide 32: Recordati in 2003

    RECORDATI IN 2003 1999 2003 CAGR Net sales 526 1000 17.4% Pharmaceuti 365 783 21.0% cals Pharmaceutical 161 217 7.7% Chemicals Ital 260 390 10.7% y Other 266 610 23.1% Countries 32

  33. Slide 33: Beyond 2003: Operations

    BEYOND 2003 Operations •Established market 1999 2003 participant in: Italy   France -  Spain   Portugal -  •International growth of Zanidip® continues •New products - licenses - own R&D 33

  34. Slide 34: Beyond 2003: R&D

    BEYOND 2003 R&D  The future of Zanidip®: - fixed association - atherosclerosis / LVH - total gene expression studies  Urogenital R&D target indications: - urge incontinence /overactive bladder - benign prostatic hypertrophy - female sexual dysfunction (possibly) 34

  35. Slide 35: Acquisizioni in Europa per un traguardo a 1.000 miliardi

    Acquisizioni in Europa per un traguardo a 1.000 miliardi Milano, 10 Maggio 2000

Recordati — Investor Presentation (May 2000) on 6ix